Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Net income | -$2.78M | -$3.26M |
| EPS (diluted) | -$0.14 | -$0.16 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$2.13M | -$5.83M |
| Capital expenditures | $74.1K | $31.6K |
| Free cash flow | -$2.20M | -$5.86M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $2.61M | $2.90M |
| Total assets | $4.46M | $6.51M |
| Total liabilities | $2.80M | $3.03M |
| Shareholders' equity | $1.66M | $3.48M |
| Retained earnings | -$16.0M | -$19.2M |
| Shares (wtd avg diluted) | 20.0M | 20.5M |
Every figure is extracted from Advanced Biomed Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.